DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Phase 1

Active, not recruiting

Conditions: Metastatic Prostate Cancer
Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Talazoparib
Drug: Tazemetostat

First Posted Date: 2021-04-15

Last Posted Date: 2024-05-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 35

Registration Number: NCT04846478

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Safe Accelerated Venetoclax Escalation in CLL

Phase 1

Recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Venetoclax
Drug: Obinutuzumab
Drug: Rituximab

First Posted Date: 2021-04-14

Last Posted Date: 2024-06-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT04843904

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia

Not Applicable

Recruiting

Conditions: Obesity
Endometrial Intraepithelial Neoplasia
Endometrial Cancer Stage I
Endometrial Carcinoma
EIN

Interventions: Other: CONCURRENT LAPAROSCOPIC HYSTERECTOMY AND WEIGHT LOSS SURGERY-Referral

First Posted Date: 2021-04-09

Last Posted Date: 2024-07-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT04839614

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

ASP8374 + Cemiplimab in Recurrent Glioma

Phase 1

Active, not recruiting

Conditions: Glioblastoma
Recurrent Glioblastoma

Interventions: Drug: ASP8374
Drug: cemiplimab

First Posted Date: 2021-04-01

Last Posted Date: 2024-05-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 14

Registration Number: NCT04826393

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States

and more 1 locations

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer

Phase 1

Recruiting

Conditions: Non-small Cell Lung Cancer
Unresectable Pancreatic Cancer
Advanced Pancreatic Adenocarcinoma
Ductal Adenocarcinoma of the Pancreas

Interventions: Drug: AGuIX
Radiation: Radiotherapy

First Posted Date: 2021-03-09

Last Posted Date: 2024-05-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT04789486

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

AWARENESS Trial (AWARENESS) of Storytelling Through Music in Healthcare Workers

Not Applicable

Completed

Conditions: Stress
Post Traumatic Stress Disorder
Work Related Stress

Interventions: Behavioral: Storytelling Through Music (STM)
Behavioral: Wait List / Storytelling Through Music-Hybrid

First Posted Date: 2021-03-01

Last Posted Date: 2024-11-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT04775524

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Abemaciclib With or Without Atezolizumab for mCRPC

Phase 2

Active, not recruiting

Conditions: Prostate Cancer
Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: Abemaciclib
Drug: Atezolizumab

First Posted Date: 2021-02-12

Last Posted Date: 2024-02-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 75

Registration Number: NCT04751929

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Improving Cognitive Function Through High-intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy

Not Applicable

Recruiting

Conditions: Chemotherapy Effect
Exercise Therapy
Cognitive Change
Breast Cancer

Interventions: Other: Attention Control
Behavioral: High-Intensity Intervals Training

First Posted Date: 2021-01-26

Last Posted Date: 2024-01-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT04724499

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Sacituzumab Govitecan Plus EV in Metastatic UC

Phase 1

Active, not recruiting

Conditions: Bladder Cancer
Urothelial Cancer
Metastatic Urothelial Carcinoma
Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter

Interventions: Drug: Sacituzumab Govitecan (SG)
Drug: Enfortumab vedotin-ejfv (EV)

First Posted Date: 2021-01-26

Last Posted Date: 2024-12-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 24

Registration Number: NCT04724018

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Taking AIM at Breast Cancer

Not Applicable

Recruiting

Conditions: Breast Cancer Stage II
Breast Cancer Stage III
Breast Cancer
Breast Cancer Stage I

Interventions: Other: CARE
Other: Home-Based Stretching
Other: TARE

First Posted Date: 2021-01-22

Last Posted Date: 2024-01-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 300

Registration Number: NCT04720209

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Home Terms & Conditions Privacy Policy